Dr John Buscombe
British Nuclear Medicine Society
Dr John Buscombe is the President of the British Nuclear Medicine Society and works as a Consultant Physician in Nuclear Medicine in Cambridge.
Theranostics in prostate cancer new or false dawn
Over the past 2 years new imaging and therapeutic options using radiolabelled prostate specific membrane antigen have been developed which enable us to see disease which cannot be found by other methods with gallium-68 PSMA PET-CT. Newer work has linked this to targeted radionuclide therapy using beta and alpha emitter labelled PSMA is previously untreatable metastatic prostate cancer which is being actively developed.
EVEN MORE SEMINARS
Sanjay Prabhu, MBBS Harvard Medical School / Boston Children’s Hospital
Evolving role of machine learning in brain tumour imaging
Matthew Bull Frimley Health NHS Foundation Trust
Pathology within the Oropharynx and Oral Cavity
Prof Sam Janes Delivering CT screening for Lung Cancer in the UK
Delivering CT screening for Lung Cancer in the UK
Estevao Mauricio Bagi Royal Brompton & Harefield Hospitals Specialist Care
Cardiac PET-CT : Rubidium-82 Myocardium Perfusion & 18F-FDG Cardiac Sarcoidosis
Dr Ben Timmis 4ways Healthcare Ltd
How to manage x-ray reporting risk with fewer consultant radiologists